CN111542520A - 作为a2a受体抑制剂的并环类衍生物 - Google Patents

作为a2a受体抑制剂的并环类衍生物 Download PDF

Info

Publication number
CN111542520A
CN111542520A CN201880062761.6A CN201880062761A CN111542520A CN 111542520 A CN111542520 A CN 111542520A CN 201880062761 A CN201880062761 A CN 201880062761A CN 111542520 A CN111542520 A CN 111542520A
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
lcms
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880062761.6A
Other languages
English (en)
Other versions
CN111542520B (zh
Inventor
陈新海
周凯
胡伯羽
肖敏亮
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KEYSTONE
CStone Pharmaceuticals Shanghai Co Ltd
CStone Pharmaceuticals Suzhou Co Ltd
Original Assignee
KEYSTONE
CStone Pharmaceuticals Shanghai Co Ltd
CStone Pharmaceuticals Suzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KEYSTONE, CStone Pharmaceuticals Shanghai Co Ltd, CStone Pharmaceuticals Suzhou Co Ltd filed Critical KEYSTONE
Publication of CN111542520A publication Critical patent/CN111542520A/zh
Application granted granted Critical
Publication of CN111542520B publication Critical patent/CN111542520B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

公开了式(Ⅰ)所示化合物或其药学上可接受的盐，并涉及其在制备治疗与A2A受体相关疾病药物中的应用。

Description

PCT国内申请，说明书已公开。

Claims (17)

  1. PCT国内申请，权利要求书已公开。
CN201880062761.6A 2017-09-28 2018-09-27 作为a2a受体抑制剂的并环类衍生物 Active CN111542520B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201710900542 2017-09-28
CN2017109005428 2017-09-28
CN2018102398242 2018-03-21
CN201810239824 2018-03-21
PCT/CN2018/107899 WO2019062803A1 (zh) 2017-09-28 2018-09-27 作为a2a受体抑制剂的并环类衍生物

Publications (2)

Publication Number Publication Date
CN111542520A true CN111542520A (zh) 2020-08-14
CN111542520B CN111542520B (zh) 2022-04-15

Family

ID=65900821

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880062761.6A Active CN111542520B (zh) 2017-09-28 2018-09-27 作为a2a受体抑制剂的并环类衍生物

Country Status (16)

Country Link
US (1) US11312715B2 (zh)
EP (1) EP3686199B9 (zh)
JP (1) JP6836693B2 (zh)
KR (1) KR102254660B1 (zh)
CN (1) CN111542520B (zh)
AU (1) AU2018341781B2 (zh)
BR (1) BR112020006185A2 (zh)
CA (1) CA3077267C (zh)
ES (1) ES2927086T3 (zh)
IL (1) IL273606B (zh)
MX (1) MX2020003732A (zh)
RU (1) RU2748993C1 (zh)
SA (1) SA520411635B1 (zh)
SG (1) SG11202002886PA (zh)
TW (1) TWI788424B (zh)
WO (1) WO2019062803A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111377873A (zh) * 2018-12-28 2020-07-07 四川科伦博泰生物医药股份有限公司 氨基嘧啶化合物及其制备方法和用途

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110655509B (zh) * 2018-06-29 2023-01-24 江苏恒瑞医药股份有限公司 2-胺基嘧啶类衍生物、其制备方法及其在医药上的应用
CN111094254B (zh) * 2018-07-12 2022-07-26 江苏恒瑞医药股份有限公司 杂芳基类衍生物、其制备方法及其在医药上的应用
WO2020192762A1 (zh) * 2019-03-28 2020-10-01 基石药业（苏州）有限公司 一种a2a受体拮抗剂的盐型、晶型及其制备方法
WO2022017434A1 (zh) * 2020-07-23 2022-01-27 上海赛岚生物科技有限公司 一类具有激酶抑制活性的化合物
CN116514803A (zh) * 2022-01-21 2023-08-01 上海赛岚生物科技有限公司 一种激酶抑制剂的盐晶型和自由碱晶型

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1437471A (zh) * 2000-06-21 2003-08-20 弗·哈夫曼-拉罗切有限公司 苯并噻唑衍生物
WO2015020565A1 (ru) * 2013-08-05 2015-02-12 Общество С Ограниченной Ответственностью "Ньювак" (Ооо "Ньювак") Замещенные [1,2,4]триазоло[4,3-a]пиридины, проявляющие свойства антогонистов аденозиновых а2а рецепторов, и их применение
CN105025899A (zh) * 2012-12-28 2015-11-04 默沙东公司 具有A2A拮抗剂性质的杂二环取代的-[1,2,4]三唑并[1,5-c]喹唑啉-5-胺化合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU699623B2 (en) 1995-04-21 1998-12-10 Neurosearch A/S Benzimidazole compounds and their use as modulators of the GABAA receptor complex
EP0976753B1 (en) * 1997-03-24 2004-01-02 Kyowa Hakko Kogyo Co., Ltd. [1,2,4]TRIAZOLO[1,5-c]PYRIMIDINE DERIVATIVES
EP1308441B1 (en) * 2000-08-11 2009-10-07 Eisai R&D Management Co., Ltd. 2-aminopyridine compounds and use thereof as drugs
ES2425476T3 (es) 2004-04-02 2013-10-15 Prana Biotechnology Limited Compuestos neurológicamente activos
ES2241496B1 (es) 2004-04-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridina.
ES2274712B1 (es) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
EP1903044A1 (en) 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
HUE025704T2 (en) * 2009-03-20 2016-04-28 Sigma Tau Ind Farmaceuti Oxidized triazolyl purine derivatives used as adenosine A2A receptor ligands and their use as medicaments
DE102012019369A1 (de) 2012-10-02 2014-04-03 Merck Patent Gmbh 7-Azaindolderivat
WO2014101120A1 (en) * 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
JP6275410B2 (ja) 2013-08-06 2018-02-07 大和ハウス工業株式会社 固定具
WO2015027431A1 (en) 2013-08-29 2015-03-05 Merck Sharp & Dohme Corp. 2,2-difluorodioxolo a2a receptor antagonists
AU2018244935A1 (en) * 2017-03-30 2019-08-15 F. Hoffmann-La Roche Ag Naphthyridines as inhibitors of HPK1

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1437471A (zh) * 2000-06-21 2003-08-20 弗·哈夫曼-拉罗切有限公司 苯并噻唑衍生物
CN105025899A (zh) * 2012-12-28 2015-11-04 默沙东公司 具有A2A拮抗剂性质的杂二环取代的-[1,2,4]三唑并[1,5-c]喹唑啉-5-胺化合物
WO2015020565A1 (ru) * 2013-08-05 2015-02-12 Общество С Ограниченной Ответственностью "Ньювак" (Ооо "Ньювак") Замещенные [1,2,4]триазоло[4,3-a]пиридины, проявляющие свойства антогонистов аденозиновых а2а рецепторов, и их применение

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111377873A (zh) * 2018-12-28 2020-07-07 四川科伦博泰生物医药股份有限公司 氨基嘧啶化合物及其制备方法和用途
CN111377873B (zh) * 2018-12-28 2023-03-28 四川科伦博泰生物医药股份有限公司 氨基嘧啶化合物及其制备方法和用途

Also Published As

Publication number Publication date
AU2018341781B2 (en) 2023-03-30
KR20200055126A (ko) 2020-05-20
ES2927086T3 (es) 2022-11-02
AU2018341781A8 (en) 2020-05-07
EP3686199A1 (en) 2020-07-29
SA520411635B1 (ar) 2022-05-24
TWI788424B (zh) 2023-01-01
CN111542520B (zh) 2022-04-15
JP2020535196A (ja) 2020-12-03
CA3077267C (en) 2021-02-16
TW201920171A (zh) 2019-06-01
IL273606B (en) 2021-05-31
EP3686199B1 (en) 2022-08-03
EP3686199B9 (en) 2022-12-07
EP3686199A4 (en) 2021-04-07
US20200239465A1 (en) 2020-07-30
KR102254660B1 (ko) 2021-05-24
RU2748993C1 (ru) 2021-06-02
CA3077267A1 (en) 2019-04-04
US11312715B2 (en) 2022-04-26
WO2019062803A1 (zh) 2019-04-04
JP6836693B2 (ja) 2021-03-03
AU2018341781A1 (en) 2020-04-30
IL273606A (en) 2020-05-31
BR112020006185A2 (pt) 2020-10-13
MX2020003732A (es) 2021-06-29
SG11202002886PA (en) 2020-04-29

Similar Documents

Publication Publication Date Title
CN110446712B (zh) 作为A2A受体抑制剂的[1,2,4]三唑并[1,5-c]嘧啶衍生物
CN111542520B (zh) 作为a2a受体抑制剂的并环类衍生物
KR102089234B1 (ko) Ask1 억제제로서의 피리딘 유도체 및 이의 제조방법과 용도
CN110944989B (zh) 作为egfr激酶抑制剂的芳基磷氧化合物
EP3333157B1 (en) Vinyl compounds as fgfr and vegfr inhibitors
US10548883B2 (en) Benzotriazole-derived α and β-unsaturated amide compound used as TGF-β RI inhibitor
CN111683928B (zh) 作为fgfr抑制剂的吡嗪-2(1h)-酮类化合物
WO2019085933A1 (zh) 作为Wee1抑制剂的大环类化合物及其应用
CN110461855A (zh) 氮杂环丁烷衍生物
US11384065B2 (en) Heterocyclic compound as CSF-1R inhibitor and use thereof
JP2019524810A (ja) 抗ｈｃｍｖウイルス化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40025623

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant